Premium
O1‐02‐03: Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 ( 18 F‐AV‐45): imaging to histopathologic correlations in an end‐of‐life human subject study
Author(s) -
Clark Christopher M.,
Schneider Julie A.,
Mintun Mark M.A.,
Bedell Barry J.,
Beach Thomas G.,
Sadowsky Carl H.,
Doraiswamy P.M.,
Gamez Jose,
Sabbagh Marwan N.,
Fleisher Adam S.,
Schaerf Frederick,
Waseem Malika,
Pontecorvo Michael J.,
Hefti Franz F.,
Skovronsky Daniel M.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.211
Subject(s) - medicine , standardized uptake value , nuclear medicine , histopathology , autopsy , pathology , positron emission tomography
control subjects (HC), dementia with Lewy Body (DLB), frontotemporal lobar degeneration (FTLD), and Alzheimer’s disease (AD) patients in-vivo using 18F-Florbetaben and PET. Methods: AD (n 1⁄4 26), FTLD (n 1⁄4 11) and DLB (n 1⁄4 6) patients as well as HC (n 1⁄4 26) underwent PET imaging after iv injection of 300 MBq 18F-Florbetaben. Standard uptake value ratios (SUVR) using the cerebellar cortex as reference region were calculated between 90-120 min post injection. Results: Significantly higher SUVR in neocortical areas were observed in AD patients when compared with the other groups. Most AD patients (96%) showed diffuse cortical 18F-Florbetaben retention while 85% of HC, 91% of FTLD, and 67% of DLB subjects showed only white-matter binding. Conclusions: Cortical Ab is present in most AD subjects with progressive dementia, while FTLD subjects show no cortical 18F-Florbetaben retention. 18F-Florbetaben clearly dstinguished subjects with high Ab burden from those with low Ab burden. Longitudinal studies will establish the value of 18F-Florbetaben in predicting development of dementia.